Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Journal of Psychopharmacology

Volumn 28, Issue 11, 2014, Pages 983-992

  Johnson, Matthew W ^a   Garcia Romeu, Albert ^a   Cosimano, Mary P ^a   Griffiths, Roland R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

addiction; Hallucinogen; nicotine; psilocybin; psychedelic; smoking cessation; tobacco

Indexed keywords

PSILOCYBINE; PSYCHEDELIC AGENT; BIOLOGICAL MARKER; CARBON MONOXIDE; COTININE; NICOTINIC AGENT; SEROTONIN AGONIST;

ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GUIDED IMAGERY; HUMAN; MALE; OPEN STUDY; PILOT STUDY; SELF REPORT; SMOKING; SMOKING CESSATION; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TOBACCO DEPENDENCE; ADVERSE EFFECTS; ATTITUDE; BEHAVIOR, ADDICTIVE; CLINICAL TRIAL; DOSE RESPONSE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; PSYCHOLOGY; TOBACCO USE DISORDER; TREATMENT OUTCOME; URINE;

ATTITUDE; BEHAVIOR, ADDICTIVE; BIOMARKERS; CARBON MONOXIDE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COTININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PILOT PROJECTS; PSILOCYBINE; SEROTONIN RECEPTOR AGONISTS; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84910080652     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114548296     Document Type: Article

References (64)

1. Benowitz NL, Jacob P, Ahijevych K, et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002 ; 4: 149-159
2. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal. 2012 ; 4: 543-555
3. Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: A follow-up study. J Nerv Ment Dis. 1970 ; 150: 111-118
4. Bramer SL, Kallungal BA. Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers. 2003 ; 8: 187-203
5. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014 ; 311: 193-194
6. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci. 2012 ; 109: 2138-2143
7. Carhart-Harris RL, Leech R, Tagliazucchi E, et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Human Neurosci. 2014 ; 8: 1-20
8. Chwelos N, Blewett DB, Smith CM, et al. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quart J Stud Alcohol. 1959 ; 20: 577-590
9. Cole C, Crum RM, Ford DE. Associations between spirituality and substance abuse symptoms in the Baltimore Epidemiologic Catchment Area follow-up, 1993-1996. J Addict Dis. 2006 ; 25: 125-132
10. DiClemente CC, Prochaska JO Coping and Substance Abuse. Shiffman S Wills TA, ed. New York, NY: Academic Press ; 1985: 319-343.
11. DiClemente CC, Prochaska JO, Gibertini M. Self-efficacy and the stages of self-change of smoking. Cognit Ther Res. 1985 ; 9: 181-200
12. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerström Test for Cigarette Dependence. Nicotine Tob Res. 2012 ; 14: 75-78
13. Fantegrossi WE, Woods JH, Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol. 2004 ; 15: 149-157
14. First MB, Spitzer RL, Gibbon M, Williams JB Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I), Clinician Version, Administration Booklet. American Psychiatric Pub ; 2012 :
15. Galanter M. Spirituality and addiction: A research and clinical perspective. Am J Addict. 2006 ; 15: 286-292
16. Griffiths RR, Bigelow GE, Henningfield JE. Similarities in animal and human drug-taking behavior. Adv Subst Abuse. 1980 ; 1: 1-90
17. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011 ; 218: 649-665
18. Griffiths RR, Richards WA, Johnson MW, et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008 ; 22: 621-632
19. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 ; 187: 268-283
20. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006 ; 296: 47-55
21. Grinspoon L, Bakalar JB Psychedelic drugs reconsidered. New York: Basic Books ; 1979:
22. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 ; 68: 71-78
23. Hall SM, Humfleet GL, Muñoz RF, et al. Extended treatment of older cigarette smokers. Addiction. 2009 ; 104: 1043-1052
24. Halpern JH. The use of hallucinogens in the treatment of addiction. Addict Res Theory. 1996 ; 4: 177-189
25. Halpern JH, Pope HG. Hallucinogen persisting perception disorder: What do we know after 50 years?. Drug Alcohol Depend. 2003 ; 69: 109-119
26. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 ; 86: 1119-1127
27. Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry. 1969 ; 125: 1352-1357
28. Hood RW. The construction and preliminary validation of a measure of reported mystical experience. J Sci Study Relig. 1975 ; 14: 29-41
29. Hood RW, Ghorbani N, Watson PJ, et al. Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran. J Sci Study Relig. 2001 ; 40: 691-705
30. Hughes JR, Keely JP, Niaura RS, et al. Measures of abstinence in clinical trials: Issues and recommendations. Nicotine Tob Res. 2003 ; 5: 13-25
31. Javors MA, Hatch JP, Lamb RJ. Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction. 2005 ; 100: 159-167
32. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: Guidelines for safety. J Psychopharmacol. 2008 ; 22 (6). 603-620
33. Johnson MW, Sewell RA, Griffiths RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 2012 ; 123: 132-140
34. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA. 2006 ; 296: 56-63
35. Kabat-Zinn J Full catastrophe living: Using the wisdom of your body and mind to face stress, pain, and illness. New York: Delacorte ; 1990:
36. Killen JD, Fortmann SP, Schatzberg AF, et al. Extended cognitive behavior therapy for cigarette smoking cessation. Addiction. 2008 ; 103: 1381-1390
37. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharm. 2012 ; 26: 994-1002
38. Ludwig A, Levine J, Stark L, et al. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969 ; 126: 59-69
39. Mangini M. Treatment of alcoholism using psychedelic drugs: A review of the program of research. J Psychoactive Drugs. 1998 ; 30: 381-418
40. Marks DF The QUIT FOR LIFE Programme: An easier way to stop smoking and not start again. Leicester, UK: British Psychological Society ; 1993:
41. Marks DF, Sykes CM. Randomized controlled trial of cognitive behavioural therapy for smokers living in a deprived area of London: Outcome at one-year follow-up. Psychol Health Med. 2002 ; 7: 17-24
42. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000 ; 117: 758-763
43. Mottillo S, Filion KB, Bélisle P, et al. Behavioural interventions for smoking cessation: A meta-analysis of randomized controlled trials. Eur Heart J. 2009 ; 30: 718-730
44. Hallucinogens and Dissociative Drugs. National Institute on Drug Abuse research report series, NIH Publication ; 2001 2001:
45. LSD NIDA Infofacts. Rockville, MD: National Institute on Drug Abuse ; 2005 2005:
46. Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013 ; 14: 577-585
47. Osmond H, Albahary R, Cheek F, Sarett M The use of LSD in psychotherapy and alcoholism. Abramson HA, ed. Indianapolis, IN: Bobbs-Merrill ; 1967: 434-457.
48. Pahnke WN, Kurland AA, Unger S, et al. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970 ; 212: 1856-1863
49. Perkins KA, Conklin CA, Levine MD Cognitive-behavorial therapy for smoking cessation: A practical guidebook to the most effective treatments. New York: Routledge ; 2007:
50. Piderman KM, Schneekloth TD, Pankratz VS, et al. Spirituality in alcoholics during treatment. Am J Addict. 2007 ; 16: 232-237
51. Piedmont RL. Spiritual transcendence as a predictor of psychosocial outcome from an outpatient substance abuse program. Psychol Addict Behav. 2004 ; 18: 213-222
52. Poling A, Bryceland J. Voluntary drug self-administration by nonhumans: A review. J Psychoactive Drugs. 1979 ; 11: 185-190
53. Ross S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am. 2012 ; 35: 357-374
54. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study. Arch Gen Psychiatry. 1973 ; 28: 808-814
55. Shiffman S, West RJ, Gilbert DG. Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res. 2004 ; 6: 599-614
56. Smart RG, Storm T, Baker EFW, et al. A controlled study of lysergid in the treatment of alcoholism: The effects on drinking behavior. Quart J Stud Alcohol. 1966 ; 27: 469-485
57. Sobell LC, Sobell MB Measuring Alcohol Consumption. Litten R Allen J, ed. Rockville, MD: Humana Press ; 1992: 207-224.
58. Sykes CM, Marks DF. Effectiveness of a cognitive behaviour therapy self-help programme for smokers in London, UK. Health Promot Int. 2001 ; 16: 255-260
59. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991 ; 86: 1467-1476
60. The Health Consequences of Smoking: 50 Years of Progress: a Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health ; 2014:
61. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci. 2010 ; 11: 642-651
62. Welsch SK, Smith SS, Wetter DW, et al. Development and validation of the Wisconsin Smoking Withdrawal Scale. Exp Clin Psychopharmacol. 1999 ; 7: 354-361
63. WHO report on the global tobacco epidemic, 2011: Warning about the dangers of tobacco. Geneva, Switzerland: World Health Organization ; 2011:
64. Zernig G, Wallner R, Grohs U, et al. A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. Addiction. 2008 ; 103: 2024-2031